Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled, “Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial,”1 published online October 7, 2021, the names of 3 investigators were omitted from Supplement 3. Phyllis Suen, MD, John Flynt, MD, and Michael Krzyzak, MD, of Staten Island University Hospital, Northwell Health, Staten Island, New York, have been added. This supplement has been corrected online.
Omitted Nonauthor Collaborators. JAMA Intern Med. 2022;182(2):239. doi:10.1001/jamainternmed.2021.7668
Artificial Intelligence Resource Center